The aim is to understand how targeting cancer stem cells can predict treatment response and overcome chemoresistance in ovarian cancer.
Investigation of ascites-derived ovarian cancer organoids
Combination treatment of OH2 and cisplatin
Assessment of drug response and chemoresistance
Targeting cancer stem cells predicts response to treatment
Combination of OH2 and cisplatin effectively reverses chemoresistance
Ascites-derived organoids provide a reliable platform for individualized drug testing
Abstract
Ascites-derived OC PDOs represent a robust platform for individualized drug testing. The combination of OH2 and cisplatin offers a novel and effective strategy for circumventing chemoresistance in OC.